Eduardo Vilar-Sánchez
United StatesresearcherMale8.0Global Dominance: 0.01%Eduardo Vilar-Sánchez is a Spanish researcher and professor of Clinical Cancer Prevention at the MD Anderson Cancer Center, University of Texas. He led a groundbreaking clinical trial demonstrating the efficacy of the NOUS-209 vaccine in stimulating immune responses in individuals with Lynch syndrome, highlighting its potential in cancer interception.
Power12,167
Reach191,774
Country presence
Recent news mentions
Dr. Eduardo Vilar-Sanchez expects a larger study to begin early next year based on the promising results of the vaccine tested by Norton.
Testing is underway on vaccines to intercept brewing colon cancer before it takes rootCNN·United States· 2026-08-09
United States· 2026-08-09
Eduardo Vilar-Sanchez is the trial leader of Nous-209 and discussed the potential of preventative vaccines for Lynch carriers.
A promising vaccine aims to prevent cancer in people with Lynch syndromeThe Globe and Mail·
Canada· 2026-02-05
Canada· 2026-02-05
Eduardo Vilar-Sánchez is a Spanish researcher who led the study on the NOUS-209 vaccine.
Vacuna para prevenir el cáncer demuestra eficacia en un ensayo clínicoListín Diario – oldest Dominican newspaper, est. 1889·
Dominican Republic· 2026-01-17
Dominican Republic· 2026-01-17
